Alar Pharmaceuticals Inc. (abbreviated as Alar), a new drug development company, was established in 2016. We focus on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and major depressive disorder.
We're tracking ALAR Pharmaceuticals Inc.'s market expansion
How ALAR Pharmaceuticals Inc.'s international expansion compares to its competitors
ALAR Pharmaceuticals Inc.YouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 ALAR Pharmaceuticals Inc.You | 0 | 0 | — | 0 | 0 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Alar Pharmaceuticals' ALA-1000, a long-acting buprenorphine injection, shows efficacy and safety in treating osteoarthritis pain in dogs for at least one month.
Alar Pharmaceuticals announced positive Phase 1 results for ALA-3000, a long-acting ketamine injection for treatment-resistant depression, demonstrating favorable safety, sustained-release profile, and clinically meaningful antidepressant effects without dissociation or sedation.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about ALAR Pharmaceuticals Inc.'s business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
